Table 2.
Gene Alterations Detected on FMI NGS Screening*
| N (%) (n=27) |
|
|---|---|
| Study Eligibility Alterations (FGFR+) | |
| FGFR1 amplification | 23(85%) |
| FGFR3 S249C | 2(7%) |
| FGFR3 amplification | 2(7%) |
| FGFR3 fusion | 1(4%) |
| Number of FGFR Gene Alterations | |
| 1 | 26(96%) |
| 2 | 1(4%) |
| Tumor Mutation Burden Score (N=25)** | |
| Median | 10.88 |
| Range | 2.42–21.77 |
| Interquartile Range | 8.46–15.72 |
| <10 | 12 (48%) |
| ≥10 | 13 (52%) |
| Other Concomitant Gene Alterations | |
| Short Variants | |
| TP53 | 26(96%) |
| MLL2 | 5(19%) |
| CDKN2A, NF1, NFE2L2 | 3(11%) |
| FBXW7, LRP1B, PAX5, SMAD4 | 2(7%) |
| BRCA2, CREBBP, DAXX, | 1(4%) |
| EP300, GATA2, HRAS, KDM6A, | |
| MYD88, NOTCH1, PALB2, | |
| PIK3R1, PTCH1, PTEN, RB1, | |
| RNF43, STAG2, TSC1 | |
| Copy Number Alterations | |
| ZNF703 | 18(67%) |
| MYST3 | 10(37%) |
| SOX2 | 9(33%) |
| PIK3CA, RICTOR | 6(22%) |
| MYC | 5(19%) |
| CDKN2A, CDKN2B | 4(15%) |
| AKT2, FGF10 | 3(11%) |
| CTNNB1, FGF12, GNAS, IRS2, | 2(7%) |
| KDM5A, KDM6A, NF1, PTEN | |
| AKT1, ARFRP1, ARID1A, | 1(4%) |
| AURKA, AXL, BAP1, BCL2L2, | |
| CCND1, CDK8, ERBB2, ERBB3, | |
| FGF19, FGF3, FGF4, FLT3, JUN, | |
| KDR, KIT, KRAS, MCL1, | |
| MTOR, NFKBIA, NKX2–1, | |
| NRAS, PDGFRA, PRSS8, RB1, | |
| RPTOR, SRC, TSC1, ZNF217 | |
| Rearrangements | |
| LRP1B | 2(7%) |
| ARID1A, BRCA2, CDKN2A, | 1(4%) |
| PRDM1, PTEN, ROS1 |
*
Full list of alterations is included as Supplementary Table
**
TMB was calculated as the number of somatic, coding, short variants, excluding known driver mutations, per megabase of the genome interrogated; TMB score was not evaluable for 2 patients.